Titles
- Enforcement policy for remote ophthalmic assessment and monitoring devices during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff1
- Enforcement policy for sterilizers, disinfectant devices, and air purifiers during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff1
- Enforcement policy for ventilators and accessories and other respiratory devices during the coronavirus disease 2019 (COVID-19) public health emergency: guidance for industry and Food and Drug Administration staff1
- Enforcement policy for viral transport media during the Coronavirus disease 2019 (COVID-19) public health emergency: guidance for commercial manufacturers, clinical laboratories, and Food and Drug Administration staff1
- Enforcement policy--OTC sunscreen drug products marketed without an approved application1
- Enforcement priorities for electronic nicotine delivery systems (ENDS) and other deemed products on the market without premarket authorization1
- Enforcement priorities for electronic nicotine delivery systems (ENDS) and other deemed products on the market without premarket authorization (revised)1
- Enhancements needed in the tracking and collection of Medicare overpayments identified by ZPICS and PSCS1
- Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products1
- Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness1
- Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC1
- Eosinophilic esophagitis: developing drugs for treatment1
- Epidermolysis bullosa: developing drugs for treatment of cutaneous manifestations1
- Establishing effectiveness for drugs intended to treat male hypogonadotropic hypogonadism attributed to nonstructural disorders1
- Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff1
- Evaluating drug effects on the ability to operate a motor vehicle1
- Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff1
- Evaluation of devices used with regenerative medicine advanced therapies1
- Evaluation of internal standard responses during chromatographic bioanalysis: questions and answers1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1